An integrated analysis reveals the oncogenic function of lncRNA LINC00511 in human ovarian cancer

Abstract

Ovarian cancer is one of the most common female reproductive system malignancies worldwide. Recently, the aberrant long noncoding RNAs (lncRNAs) expression has been identified in multiple cancers. Emerging evidence has highlighted the critical roles of lncRNAs in carcinogenesis and tumor progression, including ovarian cancer. The objective of this study is to comprehensively analyze lncRNAs expression pattern, and explore their clinical significance and underlying mechanism in human ovarian cancer. In this study, we found hundreds of dysregulated lncRNAs in ovarian cancer by performing genome‐wide analysis using RNA sequencing data from Genotype‐Tissue Expression (GTEx) and The Cancer Genome Atlas (TCGA) project, and three microarray datasets from Gene Expression Omnibus (GEO). Moreover, our results revealed that up‐ or down‐regulation of some lncRNAs expression in ovarian cancer is accompanied by their genomic loci copy number amplification or deletion. Importantly, some lncRNAs expression levels are significantly associated with ovarian cancer patients’ poor prognosis. Further experimental validation and mechanistic investigation indicate that LINC00511 exerts oncogenic function in ovarian cancer cells through interacting with EZH2 and repressing P21 expression. Taken together, the findings in the current study may provide a useful resource of novel ovarian cancer associated lncRNAs and potential diagnostic biomarker and therapeutic targets for ovarian cancer.

LINC00511 promotes the malignant phenotype of clear cell renal cell carcinoma by sponging microRNA-625 and thereby increasing cyclin D1 expression

“…Moreover, expression of LINC00511 is reported to be an independent prognostic factor of overall survival among patients with hepatocellular carcinoma [29]. LINC00511 is also overexpressed in non–small cell lung cancer [30], pancreatic ductal adenocarcinoma [31], tongue squamous cell carcinoma [32], breast cancer [33, 34], osteosarcoma [35], glioma [36], ovarian cancer [37], and thyroid carcinoma [38]. Nonetheless, few studies have illustrated the expression status of LINC00511 in ccRCC.…”

Long intergenic non‐coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo

“…For example, one previous study reveals that LINC00511 overexpression is correlated with worse OS and it is an independent prognosis factor for OS in patients with liver cancer . Another study discloses that LINC00511 high expression correlates with worse OS in patients with ovarian cancer . Compared with these previous studies, we discovered the different results that LINC00511 expression was correlated with prolonged OS and LINC00511 high expression was an independent factor that improved OS in patients with osteosarcoma.…”

“…Long non‐coding RNAs (lncRNAs) are a group of non‐protein coding RNAs with the length exceeding 200 nucleotides, which display multiple biological functions (including chromatin modification, transcriptional regulation, and post‐transcriptional regulation), and previous research reveals that lncRNA presents with potential as prognostic biomarker for cancer . Among the reported lncRNAs, long intergenic non‐coding RNA 511 (LINC00511) is proposed to be an oncogene in several cancer cells (such as bladder, breast, and lung cancer cells), and its high expression is correlated with worse prognosis in patients with different cancers (such as liver cancer and ovarian cancer) . These previous studies suggest that LINC00511 is highly expressed in tumor tissues and acts as an oncogene in several cancers, whereas its function in osteosarcoma still remains unclear.…”

LINC00511 as a prognostic biomarker for human cancers: a systematic review and meta-analysis

“…LINC00511, a newly identified lncRNA, has been reported to be upregulated and to have an oncogenic function in diverse cancers including lung cancer, breast cancer, pancreatic cancer, cervical cancer, liver cancer, ovarian cancer and glioma. Its underlying mechanisms of action include promotion of proliferation, tumorigenesis, cell cycle progression, invasion, migration, metastasis and chemoresistance and inhibition of apoptosis [16][17][18][19][20][21][22]24]. More importantly, upregulated LINC00511 has been associated with prognosis, suggesting that it can represent a biomarker for prognosis in cancer patients.…”

“…Recent studies found that LINC00511 is overexpressed in various type of cancers including breast cancer, ovarian cancer, liver cancer, pancreatic cancer, lung cancer and glioma. LINC00511 is an oncogene which plays a negative regulatory role in cell proliferation, cell cycle progression, apoptosis, invasion, migration, metastasis and chemoresistance [15][16][17][18][19][20][21][22][23]. Noteworthily, overexpression of LINC00511 was shown to be a predictor for cancer prognosis [16,18,20,22,[24][25][26][27][28].…”